Intrathecal Coadministration of Bupivacaine Diminshes Morphine Dose Progression During Long-term Intrathecal Infusion in Cancer Patients

Abstract

The diminished intrathecal morphine dose increase in the combination group is considered to be due to a synergistic effect of bupivacaine on the intrathecal morphine-induced antinociception. A dose increment during long-term intrathecal infusion in cancer patients appears to be related to both disease progression and tolerance phenomena.